Toshio Fujimoto, MD. MBA. is a founding CEO of iPark Institute Co. Ltd, which has spun out from Takeda Pharmaceutical in April 2023 to operate Shonan Health Innovation Park (iPark).  

​

From 2017 to 2023, he served as General Manager of Shonan iPark, as a R&D division of Takeda Pharmaceutical. Shonan iPark is the biggest science park in Japan established in 2018 to foster open innovation. As of Sep 2023, 110 tenant companies with >2,400 residents are clustered there. Dr. Fujimoto also doubled the role of the head of Global Public Affairs in Takeda from Jan 2021 -Dec 2022. 

 

Before joining Takeda, he worked at Eli Lilly as Vice President, Medicines Development Unit Japan at Eli Lilly Japan K.K. and led clinical development and Medical Affairs. 

 

He graduated from Kyoto University, Faculty of Medicine. After completing residency at the Department of Thoracic Surgery of Kyoto University and its affiliated hospitals, he worked as a thoracic surgeon in multi-countries, including University of Freiburg in Germany and Mayo Clinic in the US. 

.